跳至主要内容
临床试验/ITMCTR1900002661
ITMCTR1900002661尚未招募未知

A randomized controlled trial for YiFei moxibustion treatment of COPD based on the regulation of NF?B/TGF-beta 1/Smad2 signaling pathway

The First Affiliated Hospital of He'nan University of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
40 至 75(—)
性别
All

入选标准

  • 1. Diagnosis was consistent with Stable Chronic Obstructive Pulmonary Disease;
  • 2. The patient dialectical accord with Lung Qi Deficiency, Lung Spleen Qi Deficiency, Lung and Kidney Qi Deficiency patients;
  • 3. Aged 40 to 75 years;
  • 4. Able to tolerante YiFei moxibustion and voluntarily to join the study.

排除标准

  • 1. Patients with serious heart, brain, liver, kidney and other system diseases;
  • 2. Patients with other serious lung disease;
  • 3. Pregnant and lactating patients;
  • 4. Patients with mental illness and consciousness disturbance;
  • 5. Patients with poor compliance;
  • 6. There are patients who are allergic to the drugs involved in YiFei moxibustion;
  • 7. Patients who cannot undergo bronchoscopic alveolar lavage:
  • (1) The coagulation mechanism is severely impaired
  • (2) Cardiac insufficiency, severe arrhythmia or hypertension
  • (3) Aortic aneurysm
  • (4) Combined with asthma or active hemoptysis
  • (5) pneumothorax
  • (6) High mental tension and unable to complete bronchoscopy
  • (7) Severe superior vena cava obstruction syndrome
  • (8) The body organ extreme failure
  • 8. With respiratory infection or Acute Exacerbation of Chronic Obstructive Pulmonary Disease in past 1 month;
  • 9. Involved in other clinical trial in past 1 month.

研究者

发起方
The First Affiliated Hospital of He'nan University of Traditional Chinese Medicine

相似试验